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Abstract
Drug repurposing (DR) (also known as drug repositioning) is a process of 
identifying new therapeutic use(s) for old/existing/available drugs. It is an effective 
strategy in discovering or developing drug molecules with new pharmacological/
therapeutic indications. In recent years, many pharmaceutical companies are devel-
oping new drugs with the discovery of novel biological targets by applying the drug 
repositioning strategy in drug discovery and development program. This strategy 
is highly efficient, time saving, low-cost and minimum risk of failure. It maximizes 
the therapeutic value of a drug and consequently increases the success rate. Thus, 
drug repositioning is an effective alternative approach to traditional drug discovery 
process. Finding new molecular entities (NME) by traditional or de novo approach 
of drug discovery is a lengthy, time consuming and expensive venture. Drug 
repositioning utilizes the combined efforts of activity-based or experimental and in 
silico-based or computational approaches to develop/identify the new uses of drug 
molecules on a rational basis. It is, therefore, believed to be an emerging strategy 
where existing medicines, having already been tested safe in humans, are redirected 
based on a valid target molecule to combat particularly, rare, difficult-to-treat 
diseases and neglected diseases.
Keywords: drug repurposing, drug discovery, in silico repositioning, activity-based 
repositioning, target-based screening, therapeutic indication
1. Introduction
Drug repurposing (DR) is also known as drug repositioning, drug re-tasking, drug 
reprofiling, drug rescuing, drug recycling, drug redirection, and therapeutic switch-
ing. It can be defined as a process of identification of new pharmacological indica-
tions from old/existing/failed/investigational/already marketed/FDA approved 
drugs/pro-drugs, and the application of the newly developed drugs to the treatment 
of diseases other than the drug’s original/intended therapeutic use. It involves 
establishing new therapeutic uses for already known drugs, including approved, 
discontinued, abandoned and experimental drugs [1–3]. Traditional drug discovery 
is a time-consuming, laborious, highly expensive and high risk process. The novel 
approach of drug repositioning has the potential to be employed over traditional 
drug discovery program by mitigating the high monetary cost, longer duration of 
development and increased risk of failure. It confers reduced risk of failure where a 
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failure rate of ~45% is associated due to safety or toxicity issues in traditional drug 
discovery program with additional benefit of saving up to 5–7 years in average drug 
development time [4, 5]. In recent years, the drug repositioning strategy has gained 
considerable momentum with about one-third of the new drug approvals corre-
spond to repurposed drugs which currently generate around 25% of the annual rev-
enue for the pharmaceutical industry [6]. It has been accounted that approximately 
30% of the US Food and Drug Administration (FDA) approved drugs and biologics 
(vaccines) are repositioned drugs. According to recent estimates, pharmaceutical 
industries have significantly placed the market for repurposed drugs at $24.4 billion 
in 2015 with projected growth up to $31.3 billion in 2020. The first example of drug 
repositioning was an accidental discovery/serendipitous observations in the 1920s. 
After about a century of development, more approaches were developed for acceler-
ating the process of drug repositioning. Some most successful and best-known 
drugs that have been emerged out of the DR approach are sildenafil, minoxidil, 
aspirin, valproic acid, methotrexate etc. [7]. For example, sildenafil originally 
developed for the treatment of hypertension and angina pectoris has currently been 
used to treat erectile dysfunction.
2. Traditional drug discovery vs. drug repurposing
The traditional approach to drug discovery involves de novo identification and of 
new molecular entities (NME), which include five stages: discovery and preclinical, 
safety review, clinical research, FDA review, and FDA post-market safety monitoring. 
It is a time-consuming and costly process with high risk of failure [8]. On the other 
hand, there are only four stages in drug repositioning, which include compound 
identification, compound acquisition, development, and FDA post-market safety 
monitoring [9] (Figure 1). With the advancement of bioinformatics/cheminformat-
ics tools and availability of huge biological and structural database, drug reposition-
ing has significantly decreased the time and cost of the drug development with 
reduction in risk of failure. In recent years, the use of in silico techniques along with 
the application of structure-based drug design (SBDD) and artificial intelligence 
(AI) technology has further accelerated the drug purposing process [10, 11].
However, the repositioning strategy of using approved therapeutics for new 
therapeutic indications has demonstrated success particularly through prior seren-
dipitous observations. The discovery of drugs by this approach is certainly advanta-
geous as depicted above over traditional drug discovery program as described below. 
For example, sildenafil (Viagra), a phosphodiesterase-5 (PDE5) inhibitor initially 
developed for coronary artery disease (angina) by Pfizer (1985) has been repurposed 
for the treatment of erectile dysfunction. It potentially reduced the development 
cost at shorter development time. Metformin (Glucophage), an oral anti-diabetic 
medication used widely in type 2 diabetes mellitus has been developed as a cancer 
therapeutic which is currently under phase II/phase III clinical trials [1, 12].
Drug repositioning has several advantages in comparison with traditional 
approaches to drug discovery. When comparing with traditional drug discovery 
program, a significant reduction of the time spent in R&D can be observed. In 
traditional approach, it is estimated that 10–16 years are spent for the develop-
ment of a new drug, while in DR the estimated time is between 3 and 12 years. It 
only costs $1.6 billion to develop a new drug using a drug repositioning strategy, 
while the drug development through traditional strategy costs around $12 billion. 
Moreover, researchers only need 1–2 years to identify new drug targets and about 
an average of 8 years to develop a repositioned drug [6, 7]. A repositioned drug does 
not require the initial 6–9 years typically required for the development of new drugs 
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by traditional process, but instead enters directly to preclinical testing and clinical 
trials, thus reducing the overall risk, time and cost of development. Reports suggest 
that repurposed drugs require approximately 3–12 years for gaining approval from 
FDA and/or European Medicines Agency (EMA) and at reduced 50–60% cost. At 
the beginning of a repositioning project, a range of pre-clinical (pharmacological, 
toxicological, etc.), and clinical efficacy and safety information is already avail-
able, as the candidate drug has already undergone through the early stages of drug 
development such as structural optimization, preclinical and/or clinical trials, in 
addition to the possibility of the candidate drug being an approved drug, having its 
clinical efficacy and safety profile. In this way, there is a reduction of the risks asso-
ciated with failures in the early stages of development, which are high in traditional 
approaches, as well as a significant reduction of cost with the possible increase in 
clinical safety and therefore, high success rate [13, 14].
Due to the availability of previously collected pharmacokinetic, toxicologi-
cal, clinical and safety data at the start of a repurposing development project, 
the advantages that are encountered with drug repurposing over traditional drug 
discovery approach are reduced time of development, lower cost of development 
and reduced risks of failure in the clinical development.
It has been estimated that the time required for development of a repositioned 
drug varies from 3 to 12 years (which is about 10–17 years in traditional discovery 
program) with substantially lower costs, which ensures the repositioning company’s 
significant savings in terms of time and capital. The average cost required to bring 
Figure 1. 
Traditional drug discovery vs. drug repurposing.
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a new drug to market is USD 1.24 billion by traditional drug development process, 
whereas in drug repurposing it costs around ≤60% expenditure of traditional drug 
discovery. Some other advantages are as follow. The primary focus of traditional dis-
covery program is to discover drugs to treat chronic and complex diseases, whereas 
by drug repositioning approach, development of drugs for rapidly emerging and 
re-emerging infectious diseases, difficult to treat diseases and neglected diseases 
(NTDs) are focused. Due to the availability of bioinformatics or cheminformatics 
approaches, huge omics (proteomics, transcriptomics, metabolomics, genomics 
etc.) data and database resources, disease targeted-based repositioning methods can 
be used to explore the unknown mechanisms of action (such as unknown targets 
for drugs, unknown drug–drug similarities, new biomarkers for diseases etc.) of 
known/existing drugs [13].
3. Strategies of drug repurposing
There are two main strategies of DR, viz., on-target and off-target (Figure 2). In 
on-target DR, the known pharmacological mechanism of a drug molecule is applied 
to a new therapeutic indication. In this strategy, the biological target of the drug 
molecule is same, but the disease is different [12].
For example, in the repositioning of minoxidil (Rogaine), an on-target profile is 
observed, since the drug acts on the same target and produces two different thera-
peutic effects. Minoxidil was transformed from an antihypertensive vasodilator 
anti hair loss drug. As an antihypertensive vasodilator, minoxidil has the property 
of widening blood vessels and opening potassium channels, which allows more 
oxygen, blood, and nutrients to the hair follicles and this pharmacological action 
helps its use in the treatment of male pattern baldness (androgenic alopecia). 
Figure 2. 
On-target and off-target strategies of drug repositioning.
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On the other hand, in the off-target profile, the pharmacological mechanism is 
unknown. Drugs and drugs candidates act on new targets, out of the original scope, 
for new therapeutic indications. Therefore, both the targets and the indications are 
new [1]. Aspirin (Colsprin) is good example of the off-target profile. Aspirin has 
been traditionally used as NSAID in the treatment of various pain and inflamma-
tory disorders. It also suppresses blood coagulation (clot formation) by inhibiting 
the normal functioning of platelets (antiplatelet drug). It is, therefore, used in the 
treatment of heart attacks and strokes. Another new use of aspirin in the treatment 
of prostate cancer has also been reported.
4. Approaches of drug repurposing
Drug repositioning has two alternative and complementary approaches, one is 
experiment-based approach and the other is in silico-based approach.
The experiment-based approach is also known as activity-based repositioning 
which refers to the screening of original drugs for new pharmacological indica-
tions based on experimental assays. It involves protein target-based and cell/
organism-based screens in in vitro and/or in vivo disease models without requiring 
any structural information of target proteins. Several approaches of experimental 
repositioning are target screening approach, cell assay approach, animal model 
approach and clinical approach [15, 16].
In contrast, in silico repositioning carries out virtual screening of public 
databases of huge drug/chemical libraries using computational biology and bioin-
formatics/cheminformatics tools. In this approach, the identification of potential 
bioactive molecules is achieved based upon the molecular interaction between drug 
molecule and protein target [17].
The differences between activity- and in silico-based approaches of drug reposi-
tioning are summarized in Table 1.
Over the past few decades, the in silico approach has gained wide popularity with 
significant success in drug discovery program. Many pharmaceutical companies 
and drug discovery research laboratories have already successfully incorporated 
the in silico tools and techniques for the drug discovery from structurally diverse 
chemical spaces since a large amount of information on the chemical structure 
bioactive compounds, structure of proteins and pharmacophore models are avail-
able in the public domain. Moreover, in silico repositioning has some advantages 
over the experimental-based approach, which includes reduced time and cost of 
development and low risk of failure. The limitation of this method is that it requires 
Activity-based approach In silico-based approach
Experimental (in vitro and in vivo) screening Computational (virtual) screening
Target-based and cell/organism-based screening 
assay
Protein target-based screening
Requires no structural information of target 
proteins and drug-induced cell/disease phenotypic 
information
Requires structural information of target proteins 
and drug-induced cell/disease phenotypic 
information
Time and labor consuming Time and labor efficient
Lower rate of false positive hits during the 
screening
Higher rate of false positive hits during the screening
Table 1. 
Differences between activity- and in silico- based approaches of drug repositioning [17, 18].
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precise structural information about drug targets and in case, the protein target is 
not available, disease specific phenotypic or genotypic profiles of drugs are required 
[19]. Figure 3 represents the approaches of drug repositioning.
In recent years, discovery scientists and researchers have combined in silico and 
experimental approaches to identify new therapeutic indications for existing drugs, 
called mixed approach. In the mixed approach, the result of computational meth-
ods is validated by pre-clinical biological experiments (in vitro and in vivo tests) and 
clinical studies. The simultaneous application of computational and experimental 
methodologies in a systematic manner offer a robust and logical approach to the 
discovery of new indications, demonstrating a greater efficiency than the discovery 
based on serendipity. Further, mixed approach offers opportunities for developing 
repositioned drugs more effectively and rapidly. This approach is credible and yet, 
reliable [20].
5. Methodologies of drug repurposing
The methodologies adopted in DR can be divided into three broad groups 
depending on the quantity and quality of the pharmacological, toxicological and 
biological activity information available. These are mainly (i) drug-oriented,  
(ii) target-oriented, and (iii) disease/therapy-oriented.
In the drug-oriented methodology, the structural characteristics of drug 
molecules, biological activities, adverse effects and toxicities are evaluated. This 
strategy is meant for identifying molecules with biological effects based on cell/
Figure 3. 
Approaches of drug repositioning.
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animal assays. This type of repositioning methodology is based on traditional phar-
macology and drug discovery principles, where studies are usually conducted to 
determine the biological efficacy of drug molecules without really knowing about 
the biological targets. Significant successes in DR have been achieved with this 
orientation profile, through serendipity or clinical observation, such as discoveries 
with sildenafil [21].
Target-based methodology comprise in silico screening or virtual high-through-
put screening (vHTS) of drugs or compounds from drug libraries/compound 
databases such as ligand-based screening or molecular docking followed by in vitro 
and in vivo high-throughput and/or high-content screening (HTS/HCS) of drugs 
against a selective protein molecule or a biomarker of interest. In this method, 
there is a significant success rate in drug discovery as compared to drug-oriented 
method, because most biological targets directly represent the disease pathways/
mechanisms [22].
The application of disease/therapy-oriented methodology in DR is relevant when 
there is more information on the disease model is available. In this case, DR can be 
guided by the disease and/or treatment based upon availability of information given 
by proteomics (disease specific target proteins), genomics (disease specific genetic 
data), metabolomics (disease specific metabolic pathways/profile) and phenotypic 
data (off-target mechanism, pharmacological targets, disease pathways, pathologi-
cal conditions, adverse and side effects etc.) concerning the disease process. It, 
therefore, requires construction of specific disease networks, recognizing genetic 
expression, considering key targets, identifying disease causing protein molecules 
related to cell and metabolic pathways of interest in the disease model [23].
Figure 4 delineates the methodologies and steps involved in drug repositioning.
Drug-based phenotypic screening and target-based methods account for more 
than 50% of the FDA approved small drug molecules and biologics. Phenotypic 
drug screening methods identify drug candidates from small molecule libraries 
Figure 4. 
Methodologies and steps involved in drug repositioning.
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by serendipitous observations. Target-based methods discover drugs based upon 
known target molecules. The treatment/therapy-based repositioning methodology 
is similar to disease-based methodology [23].
A detailed enumeration of various methodologies employed in drug reposition-
ing along with suitable examples is given in Table 2.
Methodology Type of method, 
category
Method/specific 
approach
Example(s)
Drug-oriented
Phenotypic 
screening
Blinded/ Target-based, 
Screening
In vitro and in vivo 
HTS/HCS screening
Sildenafil (erectile 
dysfunction), rituximab 
(breast cancer)
Target 3D 
structure, chemical 
structure, 
information of 
drugs and ligands
Target-based, 
Cheminformatics
In silico screening, 
ligand-based screening 
and molecular docking, 
fragment-based 
screening
Fluorouracil (lung 
cancer), etoposide 
(bladder cancer)
Drug-target 
information, 
chemical structure, 
information of 
targets and drugs
Knowledge-based, 
Bioinformatics/ 
Chem-informatics
Drug–target prediction Simvastatin, 
ketoconazole (breast 
cancer)
Clinical trial 
information and 
adverse effects
Knowledge-based, 
Bioinformatics
Drug similarity studies —
FDA approval 
labels
Knowledge-based, 
Bioinformatics
Drug similarity studies —
Disease-oriented
Available Pathway 
information
Knowledge-based, 
Bioinformatics
Discovery of disease 
mechanism and 
address of key targets
Vismodegib (skin 
cancer)
Disease omics/ 
genetics data
Signature-based 
Bioinformatics
Studying gene 
signatures/ genomics 
to identify key targets
—
Disease omics data, 
available pathway 
information, and 
protein interaction 
network
Pathway or network- 
based, Network biology
Analysis of disease-
specific pathways and 
networks to identify 
key targets
Sunitinib, dasatinib 
(breast cancer, brain 
tumor)
Therapy-oriented
Drug omics data Signature- based or 
Signature- and network- 
based, Bioinformatics 
and/or Network biology
Studying gene 
signatures
Sirolimus (acute 
lymphoblastic 
leukemia), Fasudil 
(neurodegenerative 
disorders)
Disease omics and 
drug omics data
Signature based, 
Bioinformatics
Similarities between 
drugs and diseases
Cimetidine (lung 
cancer), topiramate 
(inflammatory bowel 
disease)
Drug omics data, 
disease pathway 
and protein 
interaction network
Targeted- mechanism 
based, Network biology 
and Systems biology
Elucidating targeted 
pathways
Daunorubicin, clomifene 
(breast cancer)
Table 2. 
Some available methods of drug repositioning [23, 24].
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Several available repositioning methods depicted above in Table 2 are described 
briefly as follows:
Blinded search or screening methods involve serendipitous identification from 
biological tests/experimental screens aimed at specific disease models and drugs. 
The advantage of these methods is that they possess higher flexibility for screening 
a large number of drugs or diseases.
Target-based methods carry out in vitro and in vivo high-throughput and/
or high-content screening (HTS/HCS) of drug molecules for a protein target or 
a biomarker of interest and in silico screening of compounds or drugs from large 
compound libraries, such as ligand-based screening or molecular docking. In these 
methods, there is a higher possibility of finding useful drugs/drug leads as com-
pared to blinded search methods. It also requires less time for the entire screening 
process to complete.
Knowledge-based methods utilize bioinformatics or cheminformatics 
approaches to gather the available information of drug profile, chemical structures 
of targets and drugs, drug-target networks, clinical trial information including 
adverse effects, signaling or metabolic pathways. This information content of 
knowledge-based methods is rich enough as compared to blinded or target-based 
methods. The known information can be used to predict therefore, be used to pre-
dict the unknown new mechanisms, such as unknown targets for drugs, unknown 
drug–drug similarities, new biomarkers for diseases etc.
Signature-based methods use gene signatures derived from disease omics data 
(genomics data) with or without treatments to discover unknown off-targets or 
unknown disease mechanisms. Genomics data are publicly available as databases. 
The advantage of these methods is that they are useful to explore unknown mecha-
nisms of action of drugs. In comparison to knowledge-based methods, signature-
based methods investigate drug mechanisms at more molecular-level, such as 
changes in expression of genes by using computational approaches.
Pathway- or network-based methods make use of disease omics data, available 
signaling or metabolic pathways, and protein interaction networks to reconstruct 
disease-specific path- ways that provide the key targets for repositioned drugs. 
The advantage of these methods is that they can narrow down general signaling 
networks from a large number of proteins to a specific network with a few proteins 
(or target molecules).
Targeted mechanism-based methods integrate treatment omics data, avail-
able signaling pathway information and protein interaction networks to describe 
the unknown mechanisms of action of drugs. The advantage of these methods 
is that they are not only used to discover the mechanisms related to diseases or 
drugs, but also to identify those directly related to treatments of drugs to specific 
diseases [23–25].
6. Repositioned drugs
Drug repositioning is an alternative approach to traditional drug discovery. With 
increasing market demand many pharmaceutical companies are developing new 
drugs or new therapeutic uses from existing/old/available drugs by drug reposi-
tioning approaches in less time, yet at low cost. In drug discovery program, the 
repositioning is usually essentially carried out in two stages as described follows. In 
the first stage, the in silico screening of approved drugs against a particular disease 
target is carried out, which is followed by the second step, in which the selected 
identified molecules are further experimentally investigated both in vitro and in 
vivo in specific disease models of interest. After successful preclinical studies in the 
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second stage of repositioning, identified drug candidates enter the clinical trials 
in human subjects [24, 25]. Figure 5 delineates several potential strategies (with 
suitable examples) of drug repositioning.
Table 3 depicts examples of some repositioned drugs already developed or 
currently under development from various approved (FDA) or marketed drugs and 
investigational new drugs (IND). Some repositioned drugs currently under clinical 
trials in COVID-19 are also included in the list.
Colchicine, a well-known anti-inflammatory drug used in the treatment of 
gout and pericarditis, is currently under clinical trial for treating COVID-19 
patients. This drug has been proved to be effective in preventing massive cyto-
kine storm induced pneumonia caused by SARS-CoV-2 (severe acute respiratory 
syndrome coronavirus-2). The antiviral effect of an older antimalarial drug, 
chloroquine (used as phosphate salt) against SARS-CoV-2 infection has also been 
investigated worldwide. Studies suggest that chloroquine may be beneficial in 
preventing coronavirus induced pneumonia in COVID-19. As per recent reports 
from NIH (National Institutes of Health, US), the clinical trial of a combination 
of hydroxychloroquine/azithromycin for the treatment of COVID-19 patients 
has already been started. In this combination, both the drugs are FDA approved, 
where hydroxychloroquine is an antimalarial drug and azithromycin is an anti-
bacterial antibiotic. An anti-viral drug, favipiravir intended for the treatment of 
influenza is currently under phase-2/phase-3 clinical trials on COVID-19 patients 
around the world (China, Japan, US, India). Glenmark has initiated phase-3 trial 
on favipiravir for the treatment of COVID-19 patients in India. An investigational 
anti-retroviral drug called remdesivir (originally developed by Gilead Sciences 
Inc. for the treatment of Ebola, but failed in clinical trial) is also under clinical 
trial for treating COVOD-19 patients in several countries like China, US, UK 
and India. In India, clinical trials on favipiravir, remdesivir and colchicine are 
currently underway by CSIR (Council of Scientific & Industrial Research) labora-
tories. A fixed dose drug combination called lopinavir/ritonavir earlier approved 
Figure 5. 
Strategies of drug repositioning with examples. vHTS: virtual high-throughput screening; HTS/HCS: 
high-throughput and/or high-content screening; Strategy 1 (S1): serendipitous observation; Strategy 2 (S2): 
observance of novel activity (specific disease phenotype, rational approach); Strategy 3 (S3): new drug-target 
interaction; Strategy 4 (S4): new roles for existing protein target; Strategy 5 (S5): new biochemical pathways; 
Strategy 6 (S6): disease-specific repositioning; Strategy 7 (S7): unexpected side effects.
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to treat HIV/AIDS under the brand name Kaletra is currently being studied to 
treat COVID-19 patients in several countries. This drug combination was inves-
tigated along with the flu drug, oseltamivir (Tamiflu) to cure infection caused 
by SARS-CoV-2 in Thailand. The clinical trial of an anti-parasitic drug called 
ivermectin (used traditionally as an approved treatment in worm infestations) 
for the treatment of COVID-19 is being undertaken in several parts of the world 
after a successful in vitro effectiveness against SARS-CoV-2 infection at Monash 
University in Melbourne, Australia. The clinical trial of toclizumab, an IL-6 recep-
tor antagonist (marketed under the brand name Actemra) used for the treatment 
of inflammatory illness such as rheumatoid arthritis is also being conducted for 
the treatment of patients with COVID-19 [25, 26].
Drug, pharmacological 
category
Original indication New indication Status of 
development
Amphotericin B (AMB), 
Anti-fungal antibiotic
Fungal infections Leishmaniasis Already developed*
Aspirin, NSAID Pain and inflammation CVDs (Anti-platelet) Already developed*
Prostate cancer Under development*
Amantadine, Anti-viral Influenza PD Already developed*
Astemizole, 
Anti-histaminic
Allergic illness such as 
urticaria
Malaria Under development*
Atomoxetine, 
Anti-depressant
Depression Attention deficit, 
Hyperactivity 
disorder
Already developed*
Avermectin, Anthelmintic River blindness, 
Elephantiasis
Tuberculosis Under development*
Azithromycin, Anti-
bacterial antibiotic
Bacterial infections COVID-19 Under development*
Bromocriptine, Dopamine 
receptor antagonist
PD DM (type 2) Under development*
Bupropion, SSRI, 
Anti-depressant
Depression Smoking cessation Already developed*
Celecoxib, COX-2 inhibitor, 
NSAID
Inflammation Breast and colon 
cancer
Under development*
Chloroquine, Anti-malarial Malaria COVID-19 Under development*
Cimetidine, H2 receptor 
antagonist
Gastric ulcer Breast, lung and 
prostate cancer
Under development*
Crizotinib, ALK inhibitor Lymphoma (under 
clinical trial for ALCL)
NSCLC Already developed#
Colchicine, Anti-
inflammatory agent
Gout (Gouty arthritis) Pericarditis Already developed*
COVID-19 Under development*
Daunorubicin, Antibiotic Breast cancer Already developed*
Digoxin, Cardiotonic CVDs such as heart 
failure
Prostate Cancer Under development*
Dimethyl fumarate, 
Anti-allergic
Psoriasis Multiple sclerosis 
(MS)
Already developed*
Disulfiram, Acetaldehyde 
dehydrogenase inhibitor
Chronic alcoholism Cancer Under development*
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Drug, pharmacological 
category
Original indication New indication Status of 
development
Duloxetine, SSNRI Depression Generalized 
anxiety disorder, 
fibromyalgia, chronic 
musculoskeletal pain, 
neuropathic pain
Already developed*
Everolimus, Immune 
suppressant
Immune suppressant Pancreatic 
neuroendocrine 
tumors
Already developed*
Favipiravir, Anti-viral Influenza COVID-19 Under development*
Fluorouracil, 
Antimetabolite, 
Anti-cancer
Cancer Breast cancer Already developed*
Fluoxetine, 
Anti-depressant
Depression Premenstrual 
dysphoria
Already developed*
Gabapentin, Anti-epileptic Epilepsy Neuropathic pain Already developed*
Galantamine, AChE 
inhibitor
Neuromuscular 
paralysis
AD Already developed*
Hydroxychloroquine, 
Anti-malarial
Malaria, RA COVID-19 Under development*
Ibudilast, PDE inhibitor 
(Anti-asthmatic)
Asthma Neuropathic pain Already developed*
Imatinib, TKI 
(Anti-cancer)
CML, ALL GIST Already developed*
Isoniazid, Anti-tubercular Tuberculosis Certain types of 
tumor
Already developed*
Itraconazole, Anti-fungal Fungal infections Cancer like NSCLC 
(Anti-angiogenic)
Under development*
Ivermectin, Anthelmintic 
(Anti-parasitic)
Scabies, river 
blindness, 
helminthiasis
COVID-19 Under development*
Lopinavir/Ritonavir, 
Anti-viral
HIV/AIDS COVID-19 Under development*
Metformin, Anti-diabetic DM (type 2) Breast and colon 
Cancer, CVDs
Under development*
Methotrexate, Anti-
metabolite (Anti-cancer)
Cancer Psoriasis, RA Already developed*
Milnacipram, 
Anti-depressant
Depression Fibromyalgia Already developed*
Miltefosine, 
Anti-leishmanial
Cancer Leishmaniasis, 
Amoeba infection
Already developed*
Mifepristone, 
Antiprogestin
Termination of 
pregnancy in 
combination with 
misoprostol
Cushing’s syndrome Already developed*
Minoxidil, Vasodilator 
(Anti-hypertensive)
Hypertension Androgenic alopecia Already developed*
Nelfinavir, Anti-viral HIV/AIDS Breast cancer, 
NSCLC (under 
clinical trials)
Under development*
Nitroxoline, Anti-bacterial UTI Breast, bladder and 
pancreatic cancers
Under development*
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Drug, pharmacological 
category
Original indication New indication Status of 
development
Orlistat, Anti-obesity agent Obesity Cancer Already developed*
Penfluridol/Pimozide, 
Anti-psychotics
Psychiatric illness Breast cancer Under development*
Propranolol, β-Blocker Hypertension Migraine Already developed*
Remdesivir, Anti-viral Influenza, Ebola 
(failed in clinical trial)
COVID-19 Under development#
Retinoic acid Acne Acute leukemia Already developed*
Ribavirin, Anti-viral Viral infection such 
as RSV, hepatitis C 
infections
Cancers like 
leukemias and 
lymphomas
Under development*
Ritoximab
Ropinirole, Anti-
Parkinsonian drug
PD Restless leg 
syndrome
Already developed*
Sildenafil, PDE inhibitor Angina pectoris, 
Pulmonary arterial 
hypertension
Erectile dysfunction Already developed*
Simvastatin, 
Hypolipidemic
CVDs Lung cancer Already developed*
Sunitinib, TKI 
(Anti-cancer)
Imatinib-resistant 
GIST, RCC
Pancreatic 
neuroendocrine 
tumors
Already developed*
Tamoxifen, Anti-estrogen 
(Anti-cancer)
Breast cancer, 
Anticancer
Systemic lupus 
erythematosus
Already developed*
NTDs like 
Leishmaniasis (in 
combination with 
miltefosine)
Under development*
Thalidomide, Immune 
modulator
Immunomodulation, 
Morning sickness 
(withdrawn)
Multiple myeloma, 
Leprosy
Already developed#
Tocilizumab, IL-6 inhibitor 
(Immune modulator)
RA COVID-19 Under development*
Topiramate Fungal infections IBD Already developed*
Valproic acid, 
Anti-epileptic
Epilepsy Manic depression 
(bipolar disorder), 
migraine headache
Already developed*
Valsartan, ARB 
(Anti-hypertensive)
Hypertension, Heart 
attack
AD Already developed*
Zidovudine, Anti-viral Cancer (failed clinical 
trial)
HIV/AIDS Already developed#
*Indicates successful repositioning from FDA approved drug.
#Indicates successful repositioning from investigational new drug (IND).
AD: Alzheimer’s disease; AChE: acetylcholine esterase inhibitor; ALCL: anaplastic large cell lymphoma; ALL: 
acute lymphocytic leukemia; ALK: anaplastic lymphoma kinase; ARB: angiotensin-receptor blocker; CML: chronic 
myeloid leukemia; COVID-19: coronavirus diseases-19; COX: cyclooxygenase; CVDs: cardiovascular diseases; DM: 
diabetes mellitus; GIST: gastrointestinal stromal tumor; HIV/AIDS: human immunodeficiency virus/acquired 
immunodeficiency syndrome; IBD: inflammatory bowel disease; IL: interleukin; NSAID: non-steroidal anti-
inflammatory drug; NSCLC: non-small cell lung carcinoma; NTD: neglected tropical diseases; PD: Parkinson’s 
diseases; PDE: phosphodiesterase; RA: rheumatoid arthritis; RCC: renal cell carcinoma; RSV: respiratory syncytial 
virus; SSNRI: selective serotonin and norepinephrine reuptake inhibitor; SSRI: selective serotonin reuptake inhibitor; 
TKI: tyrosine kinase inhibitor; UTI: urinary tract infections.
Table 3. 
Examples of some repositioned drugs from approved and investigational drugs [24–29].
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7. Opportunities and challenges
On contrary to traditional drug discovery program (a complex and time 
consuming process with high cost of development and risk of failure), drug 
repositioning, reduces the time and cost of drug development. Drug reposition-
ing is also a low-risk strategy. Computational or machine learning approach has 
significantly improved the performance of drug repositioning. In comparison 
to computational approaches, using experimental approaches (such as target 
protein-based screening, cell-based assay, testing in animal model, and clinical 
testing) that provide direct evidence-based understanding of links between drugs 
and diseases are more reliable and credible. However, in recent years computa-
tional approaches are usually combined with the experimental approaches to 
identify new indications for old drugs, called mixed approaches. In this approach, 
computational methods are validated by biological experiments and clinical tests. 
Mixed approach of repositioning offers a rational and exhaustive exploration 
of all possible repositioning opportunities, taking into consideration improved 
access to available databases and technological advances. Furthermore, the R&D 
investment required for drug repositioning is lower than that for traditional drug 
discovery. Thus, drug repositioning offers an opportunity for many pharmaceuti-
cal companies to develop drugs with lower investments [27, 28]. Mixed approach 
of DR offers opportunities for developing repositioned drugs more effectively 
and rapidly. From the market perspective, a large number of diseases require new 
drugs to be treated with a potential market demand and economic impacts. For 
example, the discovery of drugs for rare/neglected diseases has a large potential 
market to explore. There is, therefore, an opportunity for repurposing of drugs 
for the treatment of rare, neglected, orphan diseases or difficult to treat diseases. 
There are over 6000 rare diseases that lack proper treatment. About 5% of them 
are being researched. Rare diseases have a large potential market to explore. Given 
the high attrition rates, substantial costs and slow pace of drug discovery and 
development, repurposing of old drugs to treat both common and rare diseases is 
increasingly becoming an attractive area of research because it involves the use of 
drug molecules with reduced risk of failure at shorter time and lower cost devel-
opment [30–33].
With the advent of technologies such as genomics, proteomics, transcriptomics, 
metabolomics, etc., and availability of huge databases resources including drug 
omics data, disease omics data, etc., there are a plenty of opportunities to discover 
drugs by drug repositioning in a collective and integrated effort of all the above 
methods/approaches mentioned above. Researchers are currently equipped with the 
latest reliable tools and data to explore the novel unknown mechanism of actions/
pathways based upon disease-specific target proteins/genes and/or specific bio-
markers associated with the progression of the disease [34, 35].
Various databases and software are available publicly for genomics, proteomics, 
metabolomics and pathway analysis. Several computational strategies are already 
developed to increase the speed and ease of the repurposing process. Some impor-
tant databases used in drug repositioning studies are outlined in Table 4.
However, opportunities come often with many challenges in drug repositioning. 
The identification of a new therapeutic indication for an existing drug poses a major 
challenge in repositioning. However, drug repositioning is a complex process involv-
ing multiple factors such as technology, commercial models, patents, and invest-
ment and market demands. Some multiple challenges which include choosing the 
right therapeutic area for the drug under investigation, issues related to clinical trials 
such as need to run new trials from start if the data from clinical or preclinical trials 
for the original drug or drug product are outdated or are not satisfactory [34, 35].
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Information 
available 
about
Database Website
Chemical 
structure
PubChem http://pubchem.ncbi.nlm.nih.gov
Drugbank http://www.drugbank.ca/
Chemspider http://www.chemspider.com
ChemDB http://www.chemdb.com
Therapeutic Target Database 
(TTD)
http://bidd.nus.edu.sg/group/cjttd/
Target 3D 
structure
RCSB Protein Data Bank (PDB) http://www.rcsb.org
OCA http://oca.weizmann.ac.il/oca-bin/ocamain
Proteopedia http://proteopedia.org
Drug-target 
information
Drugbank http://www.drugbank.ca/
Therapeutic Target Database 
(TTD)
http://bidd.nus.edu.sg/group/cjttd/
Pharmacogenetics Knowledge 
Base (PharmGKB)
http://www.pharmgkb.org/
DrugMap Central (DMC) http://r2d2drug.org/index.html
Protein 
interaction 
information
Human Protein Reference 
Database (HPRD)
http://www.hprd.org/
Biological General Repository 
for Interaction
http://thebiogrid.org/
Database of Interacting 
Proteins (DIP)
http://dip.doe-mbi.ucla.edu/dip/Main.cgi
STRING http://string-db.org/
Pathway 
information
NCI Pathway Interaction 
Database (NCI-PID)
http://pid.nci.nih.gov/
Kyoto Encyclopedia of Genes 
and Genomes (KEGG)
http://www.genome.jp/kegg/
PathwayCommons http://www.pathwaycommons.org/about/
Clinical trial 
information 
and adverse 
effects
Clinicaltrial.gov http://clinicaltrials.gov
Adverse Reaction Database 
(Canada)
http://www.fda.gov/Drugs/
SIDER http://sideeffects.embl.de/
FDA label 
information
FDALABEL (US FDA) http://www.fda.gov/ScienceResearch/
DailyMed (US FDA) http://dailymed.nlm.nih.gov/dailymed/about.cfm
Structured Product Labeling 
(SPL)
http://www.fda.gov/ForIndustry/DataStandards/
Omics data 
(Target/Drug)
NCBI-GEO http://www.ncbi.nlm.nih.gov/geo/
Sequence Read Archive (SRA) http://www.ncbi.nlm.nih.gov/Traces/sra/
ArrayExpress http://www.ebi.ac.uk/arrayexpress/
Cancer Cell Line Encyclopedia 
(CCLE)
http://www.broadinstitute.org/ccle/home
Sequence Read Archive (SRA) http://www.ncbi.nlm.nih.gov/Traces/sra/
Table 4. 
Databases used in repositioning studies [34–36].
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8. Regulatory and intellectual property issues
Traditional drug development strategies are costly, failure prone and expensive 
ventures. Therefore, drug repositioning has recently drawn considerable atten-
tion to discover drugs with new therapeutic uses with the goal to bring drugs 
out at comparatively faster rate for clinical use. Some regulatory issues that are 
commonly encountered in drug repositioning are described as follows [37, 38]. As 
per regulatory guidelines, new preclinical and/or clinical trials may be required 
to be carried out if the available data are not satisfactory and do not comply with 
the requirements of regulatory agencies such as FDA or EMA. Another important 
issue is related to patent application and intellectual property rights (IPR). There 
are no provisions of IP protection of drug discovery by repositioning approach 
as per the IP and patent laws. For repositioned drugs, IP protection is limited. 
For repositioning drugs, IP protection is limited. For example, some novel drug-
target disease associations found by repositioning researchers were confirmed 
by publications or online databases; however, it is difficult to seek IP protection 
for such associations because of the law. The IP issue prevents some repositioned 
drugs from entering even into the market [39, 40]. Moreover, some repositioning 
projects are forced to be abandoned, which is a waste of time, money and lot of 
efforts. Although many omics data and medical databases have been established, 
selecting the appropriate approach for repositioning is still a challenge due to the 
regulatory issues because massive amounts of data may not be valid if not obtained 
from reliable sources. It is, therefore, necessary that researchers or manufacturers 
must strictly adhere with standard regulatory guidelines for drug discovery by 
repositioning approaches [2, 41–43].
9. Conclusion
Traditionally, the dug repurposing has a long recorded history discovery of drug 
molecules particularly through serendipitous observations. In recent years, it has 
embarked a new avenue in the development of new therapies based upon existing/
approved medicines. The strategic drug repositioning in a more systematic and 
rational way has brought innovation with the discovery of drug molecules with 
unknown therapeutic indications. As drug repositioning approach offers significant 
reduction in R&D costs, greater chances of success, shorter research time and lower 
investment risk, it has gained increasing market demands. Because these advantages 
are beneficial for discovery scientists, drug researchers, consumers and pharma-
ceutical companies, enabling the application of novel approaches of repositioning 
strategy in the drug discovery program for almost all human diseases. Moreover, the 
use of in silico techniques along with the application of structure-based drug design 
(SBDD) and pharmacophore modeling strategies and artificial intelligence (AI) 
technology can further accelerate the process of drug purposing in the drug discov-
ery program. In the era of precision medicine, the drug repositioning strategy has 
become very much useful to establish the unknown mechanism of action of drugs 
through exploration of novel disease/metabolic/signaling pathways, or off-targets 
and target-specific mechanisms/ genetic expression profile for even genetic disor-
ders. Advancement in genomics have provided us with genomic and transcriptomic 
data in huge quantities using technologies like next generation sequencing, microar-
ray data and transcriptomics, etc. Network biology and systems biology approaches 
may add additional benefits to unveil such novel mechanisms of actions with 
through insights into drug-target interaction profile at molecular/genetic level. For 
better drug repositioning, more in-depth understanding are required to be executed 
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